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Lipid-lowering therapy in patients with renal disease. A growing
number of clinical trials have examined the effects of different lipid
lowering strategies in patients with renal disease. We carried Out a
meta-analysis to compare and contrast the relative efficacy of various
antilipemic therapies in different renal disease settings. Studies that
investigated one or more therapies designed to lower serum lipids were
combined using weighted multiple linear regression. The analysis adjusted
treatment effects for differences in baseline lipid levels and possible
placebo effects. The results showed that antilipemic therapies generally
had similar effects on lipids in different renal disease settings. In nephrotic
syndrome the greatest and most consistent reductions in low density
lipoprotein cholesterol (LDL) were seen with 3-hydroxy-3-methylglutaiyl
co-enzyme A (HMG-C0A) reductase inhibitors (regression coefficient
with 95% confidence interval in mgldl =
—63, —79 to —46). Similar results
were seen for LDL in renal transplant (—51, —57 to —45), renal
insufficiency (—62, —82 to —42), hemodialysis (—65, —80 to —50) and
continuous ambulatoiy peritoneal dialysis (CAPD) patients (—84, —104 to
—64). Fibric acid analogues had less effect on LDL, but caused greater
reductions in triglycerides: —132, —178 to —87, in nephrotic syndrome;
—69, —93 to —45 in transplant; —107, —169 to —45 in renal insufficiency;
—72, —120 to —24 in hemodialysis; and —96, —162 to —30 in CAPD. In
general, the effects of diet and other therapies were less consistent.
Despite possible limitations of this meta-analysis, the results provide a
useful framework for choosing antilipemic therapy, and point to areas for
future long-term studies examining the safety and efficacy of lipid lowering
strategies in patients with renal disease.
Abnormalities in lipoproteins are common in patients with
renal disease and may contribute to the high incidence of cardio-
vascular events in this population. A number of new lipid lowering
agents have recently been investigated; however, there have been
few comparison trials examining their relative efficacy in renal
insufficiency, the nephrotic syndrome, hemodialysis, continuous
ambulatory peritoneal dialysis (CAPD), and transplantation.
Since efficacy may depend not only on the agent itself, but also on
the magnitude and type of hyperlipidemia being treated in
different renal disease settings, the optimal management of
hyperlipidemia in an individual patient with renal disease is often
unclear.
Although there are few direct comparison trials, we used
meta-analysis to compare and contrast the relative efficacy of
different antilipemic therapies in the various clinical settings of
renal disease. We adjusted the effects of agents for differences in
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baseline lipid levels using multiple linear regression. We examined
the relative effects of lipid lowering agents and diets on fasting
triglycerides, total cholesterol, low density lipoprotein cholesterol
(LDL), and high density lipoprotein cholesterol (HDL). The
results provide a practical guide in selecting antilipemic therapy
for patients with renal disease that is based on the available
literature, and suggest areas for further investigation.
Methods
Study selection
We used MEDLINE® to locate controlled and uncontrolled
studies examining the effects of lipid-lowering therapy in patients
with renal disease. We used key word combinations that included
hyperlipidemia, cholesterol, nephrotic, hemodialysis, CAPD, and
transplantation. We also reviewed bibliographies from published
articles to identify additional studies.
Studies were included if they reported the effects of therapy on
one or more lipid parameter (cholesterol, triglycerides and/or
lipoproteins) in patients with the nephrotic syndrome, pre-dialysis
renal insufficiency, end-stage renal disease treated with hemodi-
alysis or CAPD, or patients who had received a kidney transplant.
We included only studies of therapies specifically designed to
lower lipids, such as diet, exercise and/or lipid-lowering agents. In
patients with the nephrotic syndrome we also included studies
with agents designed to reduce proteinuria without treating the
underlying cause of renal disease, for example, converting enzyme
inhibitors and non-steroidal, anti-inflammatory agents. In hemo-
dialysis patients we included studies of low molecular weight
heparin used to reduce lipid levels. We excluded studies that
incidentally examined the effects of treatment strategies that may
have affected lipids, such as the effects of dialysis membranes in
hemodialysis patients or the effects of steroid or cyclosporine
withdrawal in transplant recipients. We included abstracts only if
they were published within the past two to three years, and thus
reported results that may have not have had sufficient time to be
published in a peer-reviewed journal.
Data extracted
We extracted data on cholesterol, LDL cholesterol, triglycer-
ides and HDL cholesterol before and after therapy or placebo.
Only values measured at the beginning and end of the study
period were used to calculate the change in lipid parameters. We
also extracted data on study duration and several study design
features that have generally been felt to reflect the quality of
clinical trials (see below). In addition, we extracted data on
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patient demographic features including age, gender, and diabetes.
Since no two study diets were identical, we analyzed all diets as
one group.
Multiple linear regression
We compared the effects of lipid lowering therapies using
weighted, multiple linear regression analysis. We first examined
the effects of therapies in separate analyses of patients with
nephrotic syndrome, renal transplantation, renal insufficiency,
hemodialysis, and CAPD. In each of these renal disease settings,
separate analyses were carried out for total cholesterol, LDL,
triglycerides and HDL. We next combined all studies in order to
compare the relative effects of therapies in each of the renal
disease settings. The therapies studied in this manner included
only those examined in all of the renal disease settings, that is,
diet, HMG-CoA reductase inhibitors, fibric acid analogues, and
fish oil. In each of the multiple linear regression models we
examined the effects of lipid-lowering therapies after taking into
account possible effects attributable to baseline lipid levels. We
did this by including a predictor variable indicating the degree by
which the baseline lipid value of a study varied from the median
baseline lipid value of all studies. We also examined the effects of
study duration and medication dose. However, the analysis of
duration and dose for each lipid endpoint in each renal disease
setting could not be carried out without greatly increasing the
number of variables and the likelihood that some results would be
statistically significant by chance. Therefore, the effects of study
duration and dose were only examined by looking at their effects
across all studies, and these results should be interpreted with
caution.
The regression was weighted by the product of the estimated
inverse variance and a study quality index. The study quality index
was designed to give greater weight to studies generally consid-
ered to be of better quality. Since there is no standard study
quality index uniformly applicable to all meta-analysis, we
adopted an index that is an arbitrary compilation of numerous
characteristics generally felt to indicate study quality. A random
effects model was used to calculate the inverse variance so that
regression weight for the i-th study group was w1 = q./(s2+S2),
where q was the study quality index, s12 was the within-study
variance and S2 was the between-study group variance. The q, was
a sum of points for: clearly stated inclusion (+ 0.5) and exclusion
(+0.5) criteria, masked investigators (+1.0) and subjects (+1.0),
random allocation (+3.0), the use of a placebo (+2.0), random-
ized controlled design (+2.0), multiple agent comparison (+ 1.0),
cross-over design (+ 1.0), a diet run-in period (+2.0), a placebo
used during the run-in period (+1.0), simple before and after
treatment design with one experimental group (—3.0), publication
as a supplement, letter, or abstract (—2.0), and acknowledged
support from public funding (+ 1.0). q was normalized to a range
of zero to one. The quality index was normally distributed. The
distribution was such that a study of the 90th percentile was given
four times more weight as a study of the 5th percentile.
The within-study variance, s2 was estimated as (Sb2 + a22 5 . 5)/a where 5b and 5a were the SD of values before and
after treatment, respectively, y was the correlation coefficient
before and after treatment or placebo, and n was the number of
patients studied. When y was not known, it was estimated by
randomly selecting a value from a normal distribution with the
same mean and SD of known correlation coefficient. These were
0.62 0.29 (N = 30 studies) for cholesterol, 0.62 0.36 (N = 19)
for LDL, 0.75 0.22 (N = 19) for HDL, and 0.75 0.21 (N = 31)
for triglycerides. The between study variance, S2 was calculated as
—
.t1)2/(N — 1) — (s12/N), where M = Ip/N, N was the
number of study groups, and was the mean treatment differ-
ence. In general, the between-study variability (S2) was much
larger than the within-study variance (s2).
We carried out sensitivity analysis to test the dependence of the
results on the major assumptions. We first examined the effects of
randomly selecting the correlation coefficient used to estimate
within-study variance. We did this by randomly selecting new
values for the correlation coefficient (from a normal distribution
with a mean and SD of the distributions of known correlation
coefficients), and re-analyzing the data based on the newly calcu-
lated variances. We repeated this five times. In each case the
regression results were virtually identical. We also examined the
effects of the method used to weight the regression analysis.
Specifically, the results of the final regression models (weighted by
the product of inverse variance and study quality) were compared
to those of regression weighted by inverse variance alone, regres-
sion weighted by sample size, and regression that was unweighted.
In each case the results of these regression models were not
substantively different. Finally, we examined the effects of includ-
ing data from recent abstracts in the analysis. Among 198 study
groups, only three in nephrotic syndrome and six in transplant
recipients were from abstracts. The results of the analysis were
similar before and after excluding these abstracts (data not
shown).
Data are expressed as mean SD, and 95% confidence intervals
unless otherwise indicated. The 95% confidence intervals for the
regression coefficients were calculated by multiplying the standard
errors of the regression coefficients by 1.96. Results were consid-
ered significant for P < 0.05. The data were analyzed using the
Statistical Package for the Social Sciences [1].
Results
Study characteristics
There were 154 studies that included 173 treatment and 25
control groups, or a total of 198 study groups. The total number of
treatment and control groups (with the number of control groups
in parentheses) were: 43 (3) for patients with the nephrotic
syndrome [2—36], 40 (5) for transplant recipients [37—66], 12 (1)
for patients with chronic renal insufficiency [67—76], 85 (15) for
hemodialysis patients [77—143], and 18 (1) for patients with CAPD
[94, 108, 144 —156]. There were 15 11 (range 4 to 93) individuals
in each study group, with a total of 3065 patients and controls. The
duration of study was 26 34 (range 0.5 to 283, median = 14)
weeks. The most frequently studied therapies were diet (N = 29
groups), HMG-CoA reductase inhibitors (48), fibric acid ana-
logues (27), and fish oil (15). Of the 40 transplant study groups, 23
(57%) were made up of patients receiving cyclosporine, while all
but one were made up of patients who received prednisone.
Baseline lipid levels
There were significant differences in baseline lipid levels be-
tween study groups of different renal disease settings (Table 1).
Cholesterol and LDL were highest in patients with the nephrotic
syndrome, next highest in renal transplant recipients, and in-
creased in patients with CAPD compared to chronic renal insuf-
ficiency and hemodialysis patients. Total cholesterol, LDL and
triglycerides were not different between patients with chronic
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Table 1. Differences in baseline lipid levels
Cholesterol LDL-cholesterol Triglycerides HDL-cholesterol
Nephrotic syndrome
Renal transplantation
352 52 (43)
301 31(40)"
252 41 (35)
195 19 (23)"
275 71 (41)
237 71 (32)
45 8 (35)
53 8 (29)"
Chronic renal insufficiency
Hemodialysis
CAPD
230 50 (12)C
215 45 (76)
269 35 (18)"
145 30 (9)C
135 27 (29)C
179 47 (13)"
211 61 (11)
261 36 (83)'
305 125 (18)"
43 5 (10)
37 12 (57)'
40 8 (17)
Values are mean (of study group means) SD and (in parentheses) the number of study groups. Shared superscripts indicate P> 0.05 by ANOVA.
Table 2. Effects of antilipemic therapies on serum cholesterol in patients with renal disease
Nephrotic syndrome Transplantation Renal insufficiency Hemodialysis CAPD
Control
—8 (—28 to 12)3 1 (—10 to 12)5 7 (—4 to 19) 1 —17 (—29 to —4) 14 10 (—25 to 45) 1
Diet
—47 (—74 to —19)5 —28 (—41 to —14) 10 28 (7 to 48) 5 —35 (—53 to —18) 8 —
HMG-CoA inhibitors —86 (—107 to —66) 21 —56 (—65 to —47) 15 —52 (62 to —42) 2 —74 (—94 to —54) 3 —71 (—90 to —52) 7
Fibrates
—31 (—69 to 7)2 —38 (—50 to —26) 7 —23 (—34 to —13)3 —47 (—64 to —31) 9
—14 (—46 to 19)5
Fish oil 7 (—28 to 41)3 23 (—19 to 66) 1 42(19 to 65) 1 —33 (—51 to —14)6 11 (—33 to 56)2
Probucol —58 (—114 to —1) 2 —66 (—87 to —44) 1 — — —
Bile sequestrants —6 (—44 to 32) 2 — — —
Niacin — —48 (—76 to —20) 1 — — —
Acipimox — — —
Pantetheine — — —
—40 (—80 toO) 2 —103 (—170 to —36) 1
Antioxidants — — —
—29 (—64 to 6) 2 —
Exercise — — —
—23 (—42 to —3)5 —14 (—70 to 43) 1
Low molecular wt heparin — — —
—27 (—49 to —6) 4 —
Erythropoietin — — — —25 (—62 to 13) 2 —25 (87 to 38) 1
Carnitine — — —
—26 (—38 to —13) 21 —
ACE inhibitors
—33 (—57 to —8) 3 — — — —
NSAID's —20 (—60 to 21) 2 — — — —
Baselinea
—0(—1 to —0)43 —0(—1 to —0)40 0(0 to 0)12 0(0 to 0)76 —0(—1 to 0)18
Multiple linear regression coefficients, and (in parentheses) 95% confidence intervals, followed by the number of study groups in separate analyses
of patients in each renal disease setting. Failure of the 95% confidence interval to include zero indicates P < .05 (in bold print). The effects of therapies
were independent of differences in baseline lipid levels. Abbreviations: CAPD, continuous ambulatoiy peritoneal dialysis; HMG-CoA, 3-hydroxy-3-
methyiglutaryl Coenzyme A; ACE, angiotensin converting enzyme; NSAID, nonsteroidal anti-inflammatory drug.aChanges in cholesterol for each mgldl in baseline cholesterol above or below the median baseline for all study groups (278 mg,/dl). Negative
coefficients indicate that higher baseline cholesterol values were associated greater declines in cholesterol and vice versa.
renal insufficiency and patients with hemodialysis. Triglycerides,
were similar in most of the groups, being higher only in CAPD
compared to chronic renal insufficiency and renal transplant
recipients. HDL was highest in renal transplant recipients.
Nephrotic syndrome
The relative effects of different agents were compared among
patients with the nephrotic syndrome, while adjusting for baseline
differences in lipid levels. The HMG-CoA reductase inhibitors
caused the greatest and most consistent reductions in total
cholesterol and LDL (Tables 2 and 3). Diet also reduced choles-
terol, but the pooled effects of diet on LDL did not reach
statistical significance. Converting enzyme inhibitors reduced
cholesterol and LDL. Other agents had less consistent effects on
cholesterol and LDL. Fibric acid analogues caused the greatest
reductions in triglycerides; however, HMG-CoA reductase inhib-
itors and fish oil also reduced triglycerides (Table 4). Only
HMG-CoA reductase inhibitors increased HDL (Table 5).
Transplantation
Diet caused modest reductions in total cholesterol and LDL,
while the HMG-CoA reductase inhibitors caused the greatest and
most consistent reductions in cholesterol and LDL (Tables 2 and
3). Similar reductions in cholesterol and LDL were seen with
probucol, and probucol was examined in only one study. Nicotinic
acid reduced total cholesterol, but was examined in only one
study. The reductions in cholesterol and LDL from fibric acid
analogues tended to be less than those caused by HMG-CoA
reductase inhibition. Diet, HMG-CoA reductase inhibitors, fibric
acid analogues, and fish oil all caused significant reductions in
triglycerides that were similar to reductions associated with fibric
acid analogues (Table 4). Despite these triglyceride reductions,
increases in IrIDL were not statistically significant (Table 5).
Renal insufficiency
Few agents were studied in non-nephrotic patients with renal
insufficiency. Both HMG-CoA reductase inhibitors and fibric acid
analogues reduced total cholesterol, but only HMG-CoA reduc-
tase inhibitors significantly reduced LDL (Tables 2 and 3). Diets
and other agents failed to have significant effects on cholesterol
and LDL. Only fibric acid analogues consistently reduced triglyc-
erides (Tables 4).
Hemodialysis
Diet, HMG-CoA reductase inhibitors, and fibric acid analogues
all reduced cholesterol and LDL in patients on hemodialysis
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Table 3. Effects of antiliplemic therapies on LDL-cholesterol in patients with renal disease
Nephrotic syndrome Transplantation Renal insufficiency Hemodialysis CAPD
Control 13 (—8 to 34) 2 1 (—5 to 8)5 — —6 (—22 to 10)7 10 (—20 to 41) 1
Diet
—28 (—56 to 0)4 —21 (—36 to —7)3 —23 (—79 to 32) 3 —41 (—62 to —20) 1 —
HMG-CoA inhibitors —63 (—79 to —46) 21 —51 (—57 to —45) 10 —62 (—82 to —42) 2 —65 (—80 to —50) 2
—84 (—104 to —64) 6
Fibrates 9 (—25 to 42) 2
—36 (—45 to —26)3
—12 (—43 to 20)3 —29 (—46 to —12)4 —6 (—52 to 40) 3
Fish oil 10 (—25 to 45)2 — 7 (—43 to 57) 1 —28 (—67 to 11) 1 31 (—21 to 83) 1
Probucol —21 (—59 to 18) 2 —49 (—62 to —36) 1 — — —
Bile sequestrants —13 (—45 to 19) 2 — — — —
Pantetheine — — — —38 (—75 to —1) 1 —24 (—87 to 39) 1
Exercise — — — 7 (—17 to 30)2 —
Low molecular wt heparin — — —
—12 (—30 to 6) 2 —
Erythropoietin — — — —15 (—49 to 19) 1 —20 (—81 to 42) 1
Carnitine — — —
—11 (—27 to 5)8 —
ACE inhibitors —78 (—105 to —50) 1 — — — —
Baselin&'
—1 (—1 to 0)36 —1 (—1 to 0)22 0 (—1 to 0)9 0 (Oto 0)29 0 (—1 to 0)13
Abbreviations are in Table 2.
a Changes in LDL cholesterol for each mgldl in baseline LDL above or below the median baseline for all study groups (191 mg/dl)
Table 4. Effects of antiliplemic therapies on triglycerides in patients with renal disease
Nephrotic syndrome Transplantation Renal insufficiency Hemodialysis CAPD
Control 9 (—35 to 54) 1 —15 (—37 to 7} 4 — —17 (—42 to 7)15 —29 (—107 to 50) 1
Diet 7 (—24 to 37) 5 —59 (—84 to —33) 10 —40 (—84 to 4) 5 —58 (—99 to —17) 9 —
HMG-CoA inhibitors
—55 (—73 to —36) 19 —49 (—67 to —30) 12
—24 (—75 to 28)2 —0 (—66 to 66) 3
—37 (—85 to 11)7
Fibratcs
—132 (—178 to —87)2 —69 (—93 to —45) 5
—107 (—169 to —45)3 —72 (—120 to —24) 10 —96 (—162 to —30) 5
Fish oil —58 (—97 to —19) 4
—86 (—166 to —5)1 —70 (—187 to 48) 1
—43 (—98 to 11)6
—104 (—228 to 19)2
Probucol
—26 (—89 to 37) 2 — — — —
Bile sequestrants 90 (42 to 138) 2 — — — —
Acipimox — — — —14 (—178 to 151) 1 —
Pantetheine — — — 10 (—113 to 134) 2 —113 (—308 to 83) 1
Antioxidants -. — —
—52 (—180 to 76) 1 —
Exercise — — —
—38 (—86 to 11)6 36 (—106 to 177) 1
Low molecular wt heparin — — —
—29 (—90 to 32) 4 —
Erythropoietin — — — —40 (—186 to 105) 1 59 (—193 to 75) 1
Carnitine — — —
—30 (53 to 7) 25 —
ACE inhibitors —49 (—105 to 7) 2 — — — —
NSAID's 7 (—44 to 57) 2 — — — —
Baselinea
—0 (—1 to —0)39 —0 (—1 to —0)32
—0 (—ito 0)11 —1 (—1 to —0)83 —1 (—1 to —0)18
Abbreviations are in Table 2.
a Changes in triglycerides for each mg/dl in baseline triglycerides above or below the median baseline for all study groups (241 mg/dl)
(Tables 2 and 3). Probucol, low molecular weight heparin, exer-
cise and carnitine caused modest reductions in cholesterol, but
failed to significantly reduce LDL. The effects of other therapies
were less consistent. Triglycerides were most consistently reduced
by diet, carnitine, and fibric acid analogues (Table 4). HDL was
increased by fibric acid analogues, fish oil, and carnitine (Table 5).
Continuous ambulatoiy peritoneal dialysis
The HMG-CoA reductase inhibitors and fibric acid analogues
consistently reduced cholesterol in patients on CAPD, while only
HMG-CoA reductase inhibitors decreased LDL (Tables 2 and 3).
Other agents were examined in only one or two studies. Triglyc-
erides were reduced by fibric acid analogues (Table 4), However,
only HMG-CoA reductase inhibitors increased HDL (Table 5).
Relative efficacy compared in different renal diseases
We compared lipid changes after adjusting for differences in
baseline lipid levels for agents that were studied in each renal
disease setting (Table 6). Interestingly, there was a statistically
significant placebo effect for cholesterol among studies in hemo-
dialysis patients, while no such effect was seen for control groups
in other renal disease settings. The effects of diet on total and
LDL cholesterol appeared to be quite similar. There appeared to
be a tendency for diet to have less effect on triglycerides in
patients with the nephrotic syndrome, compared to patients in
other renal disease settings. We attempted to analyzed the effects
of specific diet components on lipid levels. However, diet included
too many different combinations of low fat, low carbohydrate, and
low protein to allow us to analyze the effects of each component.
Only low fat (similar to that recommend by the National Choles-
terol Education program [157]) was used frequently enough (41%
of diet studies) to analyze its effects separately. In general, the
effects of diet were similar whether or not low fat was used (data
not shown).
The effects of HMG-CoA reductase inhibitors on cholesterol
and LDL were also similar in the different renal disease settings
(Table 6). However, the tendency for HMG-CoA reductase
inhibitors to reduce triglycerides and increase HDL appeared to
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Table 5. Effects of antiliplemic therapies on HDL-cholesterol in patients with renal disease
Nephrotic syndrome Transplantation Renal insufficiency Hemodialysis CAPD
Control 3.2 (—15.1 to 21.4) 1 1.7 (—2.5 to 5.8)5 — —0.3 (—3.2 to 2.5) 12 —5.3 (—11.7 to 1.0) 1
Diet
—1.2 (—12.9 to 10.4)5 4.9 (—3.5 to 13.3)4 —1.1 (—4.6 to 2.3)4 4.1 (—10.2 to 18.5) 1 —
HMG-CoA inhibitors 7.1 (1.2 to 13.1) 17 3.5 (—1.1 to 8.2) 13 3.9 (—0.3 to 8.1)2 4.2 (—2.3 to 10.8)2 5.7 (1.9 to 9.5)6
Fibrates 9.2 (—5.6 to 24.0) 2 2.8 (—3.2 to 8.8) 5 5.9 (—0.7 to 12.5) 3 7.7 (0.7 to 14.6) 6 5.9 (—0.8 to 12.6) 5
Fish oil
—0.1 (—14.7 to 14.6)3 — 9.4 (—4.0 to 22.8) 1 13.0 (5.8 to 20.1)4 —3.4 (—11.2 to 4.4) 2
Probucol —6.3 (—23.9 to 11.3) 2 —13.5 (—25.1 to —2.0) 1 — — —
Bile sequestrants 2.8 (—11.3 to 16.8)2 — — — —
Niacin — 10.1 (—0.6 to 20.8) 1 — — —
Pantetheine — — — —1.5 (—15.4 to 12.4) 2 8.2 (—5.1 to 21.5) 1
Antioxidants — — —
—2.6(—13.2to8.0)2 —
Exercise — — — 3.2 (—2.4 to 8.8)5 —1.5 (—10.5 to 7.6) 1
Low molecular wt heparin — — — —1.5 (—9.6 to 6.6)2 —
Erythropoietin — — — —2.0 (—14.2 to 10.1) 2 0.3 (—9.1 to 9.7) 1
Carnitine — — — 4.6 (1.3 to 8.0) 19 —
ACE inhibitors —4.1 (—31.0 to 22.8) 1 — — — —
NSAID's —13.0 (—34.9 to 9.0) 1 — — — —
Baselinea —0.4 (—1.2 to 0.3) 34
—0.3 (—0.7 to 0.1)29 —0.2 (—1.0 to 0.6) 10 —0.1 (—0.2 to 0.1)57 —0.1 (—0.5 to 0.3) 17
Abbreviations are in Table 2.
a Changes in HDL cholesterol for each mgldl in baseline HDL above or below the median baseline for all study groups (45 mgldl)
Table 6. Effects of antilipemic therapy on lipids in renal disease
Cholesterol LDL-cholesterol Triglycerides HDL-cholesterol
Control
Nephrotic syndrome —9 (—25 to 8)3 11 (—5 to 27)2 10 (—49 to 68) 1 3.7 (—8.0 to 15.4) 1
Transplantation —1 (—16 to 13)5 —0 (—12 to 11)5 —14 (—50 to 22)4 1.1 (—4.3 to 6.4)5
Renal insufficiency 2 (—30 to 34) 1 — — —
Hemodialysis —16 (—28 to —5) 14 —27 (—40 to —13) 7 —15 (—34 to 4)15 —0.7 (—4.3 to 2.8) 12
CAPD 7 (—23 to 36) 1 6 (—17 to 30) 1 —21 (—86 to 44) 1 —5.0 (—16.7 to 6.7) 1
Diet
Nephrotic syndrome —49 (—70 to —29) 5 —35 (—56 to —15) 4 7 (—34 to 48)5 —3.1 (—10.1 to 3.9)5
Transplantation —29 (—48 to —11)10 —20 (—45 to 6) 3 —60 (—101 to —18) 10 3.9 (—7.2 to 15.1)4
Renal insufficiency —23 (—42 to —4)5 —36 (—56 to —17)3 —47 (—84 to —9)5 —1.3 (—8.5 to 5.9)4
Hemodialysis —35 (—53 to —17) 8 —51 (—77 to —25) 1 —55 (—88 to —23) 9 4.3 (—13.6 to 22.2) 1
HMG-CoA inhibitors
Nephrotic syndrome —89 (—102 to —77) 21 —69 (—79 to —58) 21 —55 (—78 to —32) 19 7.6 (3.8 to 11.3) 17
Transplantation —59 (—70 to —47)15 —52 (—62 to —42) 10 —47 (—74 to —21) 12 2.3 (—2.6 to 7.1) 13
Renal insufficiency —58 (—85 to —30) 2 —64 (—87 to —42) 2 —25 (—86 to 36) 2 4.0 (—5.7 to 13.7) 2
Hemodialysis —74 (—95 to —53) 3 —71 (—89 to —52)2 —6 (—59 to 47) 3 3.8 (—4.4 to 12.0) 2
CAPD —70 (—87 to —53) 7 —81 (—96 to —66) 6 —38 (—79 to 4) 7 5.6 (—2.2 to 13.4) 6
Fibrates
Nephrotic syndrome —34 (—62 to —7) 2 —0 (—24 to 24) 2 —132 (—191 to —73) 2 9.4 (—0.1 to 19.0) 2
Transplantation —40 (—56 to —24) 7 —35 (—53 to —18) 3 —68 (—108 to —29) 5 1.8 (5.8 to 9.4) 5
Renal insufficiency —22 (—52 to 8) 3 —18 (—44 to 9)3 —107 (—181 to —33)3 6.2 (—7.2 to 19.5) 3
Hemodialysis —47 (—64 to —30) 9 —42 (—62 to —22) 4 —76 (—115 to —38) 10 6.2 (—2.6 to 15.0) 6
CAPD
—18 (—44 to 7)5 —19 (—45 to 7)3 —100 (—156 to —43)5 5.4 (—3.8 to 14.6)5
Fish oil
Nephrotic syndrome 6 (—22 to 35) 3 11 (—16 to 38)2 —58 (—110 to —6) 4 —0.0 (—9.5 to 9.4) 3
Transplantation 22 (—37 to 81) 1 — —86 (—224 to 51) 1 —
Renal insufficiency 7 (—48 to 62) 1 —1 (—45 to 42) 1 —80 (—208 to 48) 1 9.6 (—21.7 to 40.9) 1
Hemodialysis —34 (—53 to —14) 6 —52 (—97 to —7) 1 —45 (—88 to —2) 6 12.6 (3.8 to 21.4) 4
CAPD 7 (—32 to 45)2 20 (—19 to 59) 1 —118 (—208 to —28)2 —4.7 (—20.1 to 10.8)2
Baselinea —0 (—0 to —0) 142 —0 (—1 to —0) 87 —0 (—1 to —0)132 —0.1 (—0.4 to 0.1) 104
Multiple linear regression coefficients, and (in parentheses) 95% confidence intervals, followed by the number of study groups in separate analyses
of cholesterol, LDL, triglycerides and HDL for all patients in different renal disease settings combined. Coefficients compare the relative effects of the
same agents in the different renal disease settings. Agents that were not studied in several renal disease settings were excluded. See also the legend to
Table 2.
a Changes attributable to deviations in baseline lipids above or below the median baseline for all study groups. Negative coefficients indicate that
higher baseline values were associated greater declines and vice versa.
be greatest among patients with the nephrotic syndrome and examined the effect of medication dose on the results. Interest-
kidney transplantation. The effects of fibric acid analogues on ingly, we could detect no major effects of dose for either HMG-
lipids did not appear to vary in different renal disease settings. We CoA reductase inhibitors or fibric acid analogues. The effects of
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fish oil on total cholesterol, LDL and HDL appeared to be best in
hemodialysis patients. We examined the effect of study duration
on the results. The numbers of short duration studies (defined as
duration of study less than the median duration of all studies),
were: 10 (40%) in control, 19 (66%) in diet, 19 (40%) in
HMG-CoA reductase inhibitors, 13 (48%) in fibric acid ana-
logues, and 12 (80%) in fish oil group. The only effect study
duration appeared to have on the results was that seen for fish oil
studies; the effects of fish oil on cholesterol appeared to be less in
longer studies (data not shown).
Discussion
Clinical trials often fail to provide the information that clini-
cians need in making therapeutic decisions. Most clinical trials of
lipid lowering strategies in patients with renal disease have
examined the efficacy of a particular therapy in a homogeneous
population of patients with renal insufficiency, the nephrotic
syndrome, or end-stage renal disease treated by transplantation,
hemodialysis or CAPD. However, clinicians must select from
several different therapeutic options the one that is best suited for
an individual with a unique lipid profile. The clinician needs to
know the relative efficacies of various lipid lowering strategies for
patients in different renal disease settings, taking into account
differences in baseline lipid levels. Since no single clinical trial can
address this question, we used meta-analysis to compare and
contrast the effects of various lipid lowering strategies in patients
in different renal disease settings.
Differences in baseline lipid levels in the therapeutic trials
included in the meta-analysis were similar to those reported in
epidemiologic studies (Table 1). Thus, the patients studied in
these trials appeared to be representative of patients with renal
disease in general [158—162]. For example, the increased levels of
total and LDL cholesterol in nephrotic syndrome, renal transplant
recipients and CAPD patients were of a similar magnitude as
those reported in cross-sectional studies [158, 160, 161]. Likewise,
the relatively lower levels of cholesterol and LDL in non-ne-
phrotic patients with renal insufficiency and in patients treated
with hemodialysis were similar to levels reported by others [159,
160]. The higher levels of HDL in transplant recipients and the
lower HDL levels in hemodialysis patients have also been de-
scribed in several epidemiologic studies [159—161].
The results of the meta-analysis give some useful insights
regarding the relative efficacies of lipid lowering strategies. Based
on these results and on the assumption that the risk of hyperlip-
idemia is at least as great in patients with renal disease as it is in
the general population, some specific recommendations for ther-
apy can be made. In most patients with persistent nephrotic
syndrome, therapy has been aimed at reducing high levels of LDL.
In some nephrotic patients, a converting enzyme inhibitor may
reduce proteinuria and thereby decrease LDL [31, 32], Although
few studies have addressed the efficacy of combination therapy, a
combination of diet and a HMG-CoA reductase inhibitor appears
to be a reasonable first step. In patients who require additional
therapy, a bile acid sequestrant appears to be reasonable if fasting
triglycerides are less than 200 mg/dl. Alternatively, patients with
very high triglycerides and/or reduced HDL may respond to the
addition of a fibric acid analogue. It should be pointed out,
however, that the safety and efficacy of combination therapy have
not been studied in patients with renal disease, and is an area well
suited for future research.
In renal transplant recipients therapy for hyperlipidemia has
most often be aimed at reducing LDL. Results of the meta-
analysis suggest that diet and a HMG-CoA reductase inhibitors
will generally be the best initial therapy. Doses of HMG-CoA
reductase inhibitors should be kept low in patients treated with
cyclosporine, and other agents that may cause rhabdomyolysis
should generally not be used in combination with HMG-CoA
reductase inhibitors (see below). Normotriglyceridemic patients
who need greater LDL reductions may respond to the addition of
a bile acid sequestrant. The potential for reduced bioavailability
of cyclosporine in patients treated with bile acid sequestrants has
not been adequately addressed in clinical trials. In one study of
heart transplant recipients, a bile acid sequestrant failed to alter
cyclosporine bioavailability [163]. In patients with hypertriglyceri-
demia, the combination of diet and fibric acid analogues may be
a reasonable choice. Fibric acid analogues also reduce LDL, but
not as effectively as HMG-CoA reductase inhibitors.
Non-nephrotic patients with renal insufficiency typically have
high triglycerides and low HDL. Diets have not been particularly
effective in renal insufficiency patients, and the addition of fibric
acid analogues may be the best choice in this setting. Fish oil
supplements need additional study, but in at least one investiga-
tion their use was associated with an increase in total cholesterol.
In patients with renal insufficiency and increased LDL, HMG-
CoA reductase inhibitors appear to be a reasonable option.
The lipid profiles of hemodialysis patients resemble those of
patients with renal insufficiency. For patients with high triglycer-
ides and low HDL, the results of the meta-analysis suggest the diet
and a low dose of second generation fibric acid analogue are both
attractive choices. Fish oil supplements have been examined in
several trials, but appear to be less effective than fibric acid
analogues in reducing total cholesterol and triglycerides. For the
occasional hemodialysis patient with increased LDL, HMG-CoA
reductase inhibitors are effective. Carnitine also appeared to
decrease cholesterol, triglycerides, and increase HDL but had no
effects on LDL. Thus carnitine could be considered as a thera-
peutic option in hemodialysis patients, although it is less effective
than fibric acid analogues. A number of other therapies have been
explored in hemodialysis patients, but their effects appear to be
too inconsistent to make strong recommendations regarding their
use.
Unlike patients treated with hemodialysis, CAPD patients often
have high LDL. The effect of diet on LDL has not been studied in
patients with CAPD. The results of the meta-analysis suggest that
HMG-CoA reductase inhibitors are well suited for reducing LDL
in CAPD patients. In addition, HMG-CoA reductase inhibitors
raised HDL at least as effectively as fibric acid analogues.
However, a fibric acid analogue may be the best choice for the
CAPD patient with hypertriglyceridemia.
Effective lipid lowering strategies in patients with renal disease
should take both efficacy and safety into account. Most of the
clinical trials in patients with renal disease have been too small to
provide accurate data on the incidence of adverse effects. Thus,
the incidence of adverse effects must generally be extrapolated
from the results of large surveillance trials in patients without
renal disease. However, some expected adverse effects were
confirmed in trials carried out in patients with renal disease. Bile
acid sequestrants, for example, increased fasting triglycerides in
patients with the nephrotic syndrome (Table 4). The well-known
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propensity for bile acid sequestrants to increase triglycerides in
other populations has led the National Cholesterol Education
Program to recommend avoiding these agents in patients with
baseline elevations in triglycerides [157]. Probucol decreased
HDL cholesterol in patients with the nephrotic syndrome and
transplant recipients (Table 5). Similar HDL reductions in pa-
tients without renal disease have prompted many to avoid the
routine use of probucol until primary intervention trials demon-
strate efficacy in reducing cardiovascular disease [164].
The HMG-CoA reductase inhibitors have been reported to
cause rhabdomyolysis in heart transplant recipients treated with
cyclosporine. Virtually all of the reported cases were in patients
who either received high doses, for example, 80 mg/day of
lovastatin, or combination therapy with other lipid lowering
agents known to cause muscle necrosis [165—171]. It has also been
shown that blood levels of HMG-CoA reductase inhibitors were
increased in patients treated with cyclosporine [172—174]. These
observations have led investigators to avoid high doses of HMG-
CoA reductase inhibitors and concomitant therapy with other
lipid lowering agents known to cause rhabdomyolysis in cyclospo-
rifle treated patients. The success of this strategy is documented
by the fact that not a single case of rhabdomyolysis was reported
in the 363 renal transplant recipients treated for a total of 524
patient-years in 15 studies in the present meta-analysis.
Fibric acid analogues may cause rhabdomyolysis in patients
with decreased renal function. It is now apparent that blood levels
of fibric acid derivatives are increased in patients with reduced
glomerular filtration rate. However, low doses of clofibrate and
moderate doses of second generation fibric acid analogues do not
appear to cause rhabdomyolysis in patients with renal failure.
Indeed, of the 282 patients with decreased renal function in 18
studies of fibric acid analogues treated for a total of 109 patient-
years in the present meta-analysis, none developed rhabdomyoly-
sis.
Many adverse effects are not life-threatening but may neverthe-
less decrease tolerance to therapy. Several of these adverse effects
of lipid lowering agents were mentioned, but not systematically
quantitated in the relatively small trials carried out in patients
with renal disease. Adverse effects that are not life-threatening
have been particularly prevalent in patients treated with bile acid
sequestrants (gastrointestinal symptoms) and nicotinic acid (flush-
ing and gastrointestinal symptoms). Long-acting nicotinic acid
preparations may also lead to glucose intolerance, a problem
already prevalent in many patients with renal disease [160, 1611.
It was interesting that the effects of diet, HMG-CoA reductase
inhibitors, fibric acid analogues and fish oil were generally quite
similar in different renal disease settings, once the variability in
baseline lipid levels were taken into account. Indeed, any differ-
ences in the effects of these therapies could have been due to
chance, especially considering the number of possible compari-
sons that were made. Why HMG-CoA reductase inhibitors, for
example, appeared to have a greater effect on triglycerides and
HDL in patients with the nephrotic syndrome and CAPD is
unclear. This effect could be due to chance or could be related to
similarities in the pathogenesis of the lipid disorders in these two
renal disease settings. There is evidence, for example, that the
lipoprotein abnormalities in these two renal disease settings are
related to losses of protein in the urine or dialysate. Why the
effects of fish oil on total cholesterol, LDL and HDL appeared to
be best in hemodialysis patients is also unclear, but must be
interpreted in light of the fact that placebo effects were also
greatest in hemodialysis patients.
The results of the present meta-analysis should be interpreted
with caution. It was not possible to conduct a meta-analysis
comparing each agent with a randomly allocated control group.
However, there did not appear to be any systematic bias, whereby
different agents were studied in a different manner. Nevertheless,
including both controlled and uncontrolled trials probably exag-
gerated the treatment effects. Weighting the regression by study
quality and inverse variance, and comparing the pooled results of
treatment groups with those of pooled control groups may not
have fully accounted for study design flaws that may have exag-
gerated treatment effects. As with any meta-analysis, the present
results could be affected by publication bias, if positive studies
were more often published than negative investigations. However,
the present analysis may be less subject to publication bias, since
we compared studies which were all likely to have the same bias,
that is, that the therapy being studied would lower lipids.
The study quality index we used to weight the regression
analysis was arbitrary. This was by necessity, since there is no
generally accepted study quality index applicable to the clinical
trials included in the present analysis. Nevertheless, the results of
the present analysis did not appear to be dependent on the study
quality index. Indeed, whether or not the study quality index was
included in the weighting of the regression had little effect on the
results.
None of the trials included in the present analysis examined the
effects of treatment on vascular disease or renal disease progres-
sion. Thus, which patients with renal disease should be treated
with lipid lowering therapy cannot be answered by these data.
However, a substantial amount of circumstantial evidence sug-
gests that hyperlipidemia should be treated at least as aggressively
as it is treated in patients who do not have renal disease. Whether
existing clinical guidelines for the treatment of hyperlipidemia,
that take into account multiple risk factors for cardiovascular
disease [157], are applicable to patients with renal disease is
unknown. In the absence of more specific information, clinicians
must tailor treatment decisions to individual patients. However,
the present meta-analysis provides a framework for choosing
therapy, once therapy is felt to be indicated.
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